There is a tree in China that has outlived the dinosaurs, survived ice ages, and — after 200 million years — became the single best-selling herbal supplement for the human brain. Its name is Ginkgo biloba, and for thousands of years traditional medicine has sworn by its leaves for memory. Modern science, being modern science, decided to test that claim with two of the largest, most expensive trials ever run on any supplement in history — following thousands of older adults for half a decade. What those trials found split the supplement world in two: the “prevents dementia” story was quietly buried, while a quieter, more modest benefit survived. Here is what is actually true.
📋 Simple Summary
Ginkgo biloba is an extract made from the leaves of the Ginkgo tree — the oldest living tree species on Earth, unchanged for roughly 200 million years. Millions of people take it for memory and brain health. The honest headline: the two largest and most rigorous trials ever run on it, tracking more than 5,900 older adults for five to six years, found it does not prevent dementia or slow down normal age-related memory decline. But the most up-to-date review of the evidence — the 2026 Cochrane review covering 82 studies and over 10,000 people — found ginkgo may give a small-to-moderate boost to people who already have dementia, and it has genuinely decent evidence for vertigo and dizziness. It is generally safe and very well studied, but it thins the blood, which matters if you take blood thinners or are heading into surgery. Bottom line: ginkgo is not the “memory pill” it is marketed as — but it is not worthless, either.
The detailed breakdown continues below for those who want the full science.
Published: August 16, 2026
Evidence Tier: 🥈 Silver — one of the most-studied botanicals in existence, with a mixed verdict: no dementia prevention, but modest symptomatic benefit and an excellent safety record
Category: Supplements & Compounds
⚖️ At a Glance: Pros & Cons
⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Talk to your doctor before taking any supplement. The information below is for education only.
✅ Pros (What the Evidence Supports)
- Strongest benefit: In people who already have dementia, the 2026 Cochrane review (82 studies, 10,613 participants) found small-to-moderate improvements in cognition and daily function at six months (PMID 41641880).
- Excellent safety record: Across the largest trials, ginkgo showed no meaningful difference in serious adverse events versus placebo — high-certainty evidence in people with mild cognitive impairment (PMID 41641880).
- Vertigo and dizziness: The standardized extract EGb 761 (240 mg/day) improved dizziness, balance, and gait in a 179-patient clinical trial (PMID 42568872).
- Post-stroke dementia: A meta-analysis of four trials (488 patients) found significant cognitive benefit in people who developed dementia after a stroke (PMID 41908799).
❌ Cons (What the Evidence Doesn’t Support or Warns About)
- Biggest limitation: Ginkgo does NOT prevent dementia or slow cognitive decline — the GEM trial (3,069 adults) and the GuidAge trial (2,854 adults) both came up empty (PMID 19017911, PMID 22959217).
- No clear benefit for healthy adults: A network meta-analysis of 29 trials found ginkgo no better than placebo on most memory and attention measures in healthy people (PMID 41678913).
- Bleeding risk: Ginkgo has blood-thinning (antiplatelet) effects and can increase bleeding, especially combined with blood thinners or before surgery.
- Liver watch: Some trials reported minor elevations in liver enzymes, so long-term users should have liver function monitored (PMID 42157337).
What Is Ginkgo Biloba?
Ginkgo biloba is a leaf extract from the Ginkgo tree, a species so ancient it is often called a “living fossil.” It has no close living relatives, has survived essentially unchanged for around 200 million years, and a single tree can live for over 1,000 years (PMID 42363742). Traditional Chinese medicine has used the leaves and seeds for thousands of years. The modern supplement story began in 1960s Germany, when a company called Dr. Willmar Schwabe developed a standardized extract known as EGb 761 — and that standardization is the single most important thing to understand about ginkgo.
Raw ginkgo leaf powder is not what was tested in the big trials. The evidence — positive and negative — rests almost entirely on standardized extracts like EGb 761 (and similar products such as LI 1370 and GBE50). These are standardized to two groups of active molecules:
- Flavone glycosides (typically 24%) — plant antioxidants, including quercetin, kaempferol, and isorhamnetin.
- Terpene lactones (typically 6%) — a family unique to ginkgo, made up of ginkgolides A, B, and C plus bilobalide. These are the compounds thought to be responsible for ginkgo’s effects on blood flow and platelets.
The Ginkgo tree’s own longevity is a nice piece of irony. A 2026 study of Ginkgo trees aged 1 to 1,070 years found the species maintains its chemical defenses — and its vigor — through age-dependent epigenetic changes (PMID 42363742). But the plant’s durability does not automatically transfer to the humans who take its extract. That transfer is exactly what the clinical trials were designed to test.
How It Works
Ginkgo’s proposed mechanisms map neatly onto the biology of an aging brain, which is why the supplement community has always found it plausible:
- Antioxidant action: The flavonoids neutralize free radicals — reactive molecules that damage cells and accumulate with age (PMID 42207745).
- Blood flow and platelets: The ginkgolides, particularly ginkgolide B, block a molecule called platelet-activating factor (PAF). This relaxes blood vessels and reduces platelet clumping — which improves circulation, but is also exactly why ginkgo can increase bleeding (PMID 42207745).
- Mitochondrial protection: Mitochondria are the power plants inside your cells, and their decline is a core hallmark of aging. A 2026 study in human stem-cell models of aging found ginkgo extract restored ATP production, improved mitochondrial membrane potential, and reduced oxidative stress in aged neurons and support cells (PMID 42351995).
- Anti-inflammatory and neuroprotective: Ginkgo dampens neuroinflammation and protects neurons against toxic insults in preclinical models (PMID 42207745, PMID 42443567).
All of this is biologically plausible. The question the trials had to answer was whether any of it translates into a real difference in a human brain — and here the answer turned out to be far more nuanced than the marketing suggests.
The Longevity Connection
🧠 Brain and cognition — the claim that was refuted. This is the whole reason people buy ginkgo, and it is where the evidence is weakest. The GEM study (Ginkgo Evaluation of Memory) randomized 3,069 cognitively intact adults aged 75+ to 240 mg/day of ginkgo or placebo for a median of 6.1 years. Result: ginkgo did not reduce the incidence of dementia or Alzheimer’s disease (PMID 19017911). A companion analysis found it also did not slow cognitive decline (PMID 20040554). The European GuidAge trial replicated the null result in 2,854 adults aged 70+ followed for five years (PMID 22959217). Between them, these are two of the largest, longest prevention trials ever run on any supplement — and both were negative.
🧠 Symptom relief in existing dementia — a modest “yes.” Here the picture flips slightly. The 2026 Cochrane review (82 studies, 10,613 participants) found that in people who already have dementia, ginkgo may produce small-to-moderate improvements in global status, cognition, and daily function at six months — though the certainty of that evidence is low (PMID 41641880). In people with mild cognitive impairment (MCI) or just “subjective” memory complaints, there was little or no benefit. A separate meta-analysis of four trials in people who developed dementia after a stroke found significant cognitive and functional benefit from 240 mg/day of EGb 761 (PMID 41908799).
🙋 Healthy adults — no clear effect. For the person with no cognitive problems who hopes ginkgo will make them sharper, the evidence is discouraging. A 2026 network meta-analysis of 29 randomized trials in healthy adults found ginkgo was no better than placebo on most memory and attention measures — and was actually outperformed by high-dose Bacopa monnieri for working memory (PMID 41678913).
🌀 Vertigo, dizziness, and balance. This is ginkgo’s most underrated strength. A 2026 open-label trial of 179 patients with vertigo and dizziness of various causes found 240 mg/day of EGb 761 improved dizziness symptoms, posture, and gait over 12 weeks (PMID 42568872). Meta-analyses of the same extract have reported similar benefits for vestibular disorders.
🩸 Metabolic health — early and preliminary. A 2026 meta-analysis of eight trials (1,507 people with metabolic syndrome or type 2 diabetes) found ginkgo modestly lowered fasting glucose (−13.88 mg/dL) and improved insulin resistance, and reduced inflammatory markers like CRP, TNF-α, and IL-6 — but the authors flagged short trial durations and possible publication bias, and ginkgo did not improve HbA1c (PMID 42157337). A separate meta-analysis found only a weak, mixed effect on cholesterol (PMID 42102021). Treat these as hypothesis-generating, not a reason to take ginkgo.
🫀 Blood vessels and calcification. Preclinical work found a ginkgo extract (GBE50) inhibits vascular calcification — the stiffening of arteries that accelerates with age — by blocking inflammatory pathways (PMID 42155821). This is interesting mechanism work in cells and animals, not yet a human result.
Key Studies
| Study | Design | Key Finding |
|---|---|---|
| GEM — DeKosky 2008 (PMID 19017911) | RCT, double-blind, placebo (n=3,069, median 6.1 yrs) | 240 mg/day did NOT reduce incidence of dementia or Alzheimer’s disease. |
| GEM cognitive — Snitz 2009 (PMID 20040554) | RCT (same GEM cohort) | Ginkgo did NOT slow cognitive decline in older adults. |
| GuidAge — Vellas 2012 (PMID 22959217) | RCT, double-blind, placebo (n=2,854, 5 yrs) | No reduction in Alzheimer’s disease incidence after five years. |
| Cochrane 2026 (PMID 41641880) | Systematic review (82 studies, 10,613 participants) | No benefit in MCI; small-to-moderate benefit for dementia symptoms; no increase in serious adverse events. |
| Bacopa vs Ginkgo NMA 2026 (PMID 41678913) | Network meta-analysis (29 RCTs, 2,107 healthy adults) | Ginkgo no better than placebo on most measures in healthy adults; high-dose Bacopa outperformed. |
| Post-stroke dementia meta-analysis 2025 (PMID 41908799) | Meta-analysis (4 RCTs, 488 patients) | 240 mg/day EGb 761 significantly improved cognition and daily function in post-stroke dementia. |
| Vertigo trial 2026 (PMID 42568872) | Open-label, multicentre (n=179, 12 wks) | EGb 761 (240 mg/day) improved dizziness, posture, and gait across vestibular syndromes. |
| iPSC mitochondrial study 2026 (PMID 42351995) | Preclinical (human stem-cell aging model) | Ginkgo restored ATP production and membrane potential and cut oxidative stress in aged neurons and astrocytes. |
| Metabolic syndrome meta-analysis 2026 (PMID 42157337) | Meta-analysis (8 RCTs, 1,507 subjects) | Lowered fasting glucose and inflammatory markers; no HbA1c change; authors caution publication bias. |
Dosing and Safety
The dose that appears in almost every meaningful trial is 120–240 mg/day of a standardized extract (usually EGb 761, standardized to 24% flavone glycosides and 6% terpene lactones), typically taken as 120 mg twice daily or 240 mg once daily:
| Goal | Dose Used in Trials | Notes |
|---|---|---|
| Dementia symptom support | 240 mg/day (often 120 mg twice daily) | The dose in the positive Cochrane and post-stroke analyses (PMID 41641880, PMID 41908799). |
| Vertigo / dizziness | 240 mg/day for 12 weeks | Dose used in the 179-patient vertigo trial (PMID 42568872). |
| Prevention of decline (refuted) | 240 mg/day | The GEM and GuidAge trials used this dose and found no prevention benefit (PMID 19017911, PMID 22959217). |
Form selection: Use a standardized extract (EGb 761 or equivalent with stated flavone-glycoside and terpene-lactone content), not raw ginkgo leaf powder. Effects, where they occur, typically take 4–6 weeks to appear. A 2026 dosing review across global regulators (FDA, EMA, Health Canada) found 120–240 mg/day of EGb 761 to be the consistent, evidence-based range (PMID 42269907).
Safety notes:
- Bleeding is the main real risk. Ginkgo’s antiplatelet activity means it can increase bleeding and bruising, and it can interact with blood thinners including warfarin, aspirin, clopidogrel, and NSAIDs. The GEM trial observed more hemorrhagic (bleeding) strokes in the ginkgo group than placebo — a non-significant trend, but a reminder to take this seriously (PMID 19017911).
- Stop before surgery. Most guidance is to discontinue ginkgo at least two weeks before elective surgery.
- Liver enzymes. A 2026 meta-analysis noted minor but statistically significant elevations in liver enzymes (ALT/AST) with ginkgo, with no clinical liver injury reported — worth periodic monitoring with long-term use (PMID 42157337).
- Common, usually mild side effects: stomach upset, headache, dizziness, and allergic skin reactions. These are the most frequently reported (PMID 41641880).
- Seizure risk from the seeds, not the leaf extract. Raw or lightly roasted ginkgo seeds contain a toxin called ginkgotoxin (a vitamin B6 lookalike) that can trigger seizures. The standardized leaf extract contains negligible ginkgotoxin, but people with epilepsy should still use caution.
- Pregnancy and breastfeeding: insufficient safety data — avoid.
❓ Common Questions About Ginkgo Biloba
What is ginkgo biloba and how does it work?
Ginkgo biloba is an extract from the leaves of the Ginkgo tree, the oldest living tree species on Earth. It contains two main groups of active compounds: flavonoids, which act as antioxidants, and ginkgolides and bilobalide, which relax blood vessels, reduce blood clotting, and protect mitochondria — the energy power plants inside your cells.
What does the evidence actually show?
The evidence is genuinely mixed — 🥈 Silver overall. The two largest trials ever run (over 5,900 older adults) found ginkgo does NOT prevent dementia or slow memory decline. But the 2026 Cochrane review of 82 studies found it may give a small-to-moderate boost to people who already have dementia, and it has solid evidence for vertigo and dizziness. For healthy adults hoping to sharpen an already-normal brain, there is no clear benefit.
What’s the right dose?
The dose used in almost every meaningful trial is 120–240 mg per day of a standardized extract (usually EGb 761, standardized to 24% flavone glycosides and 6% terpene lactones), taken as 120 mg twice daily or 240 mg once daily. Any benefit typically takes 4–6 weeks to appear. Always use a standardized extract rather than raw leaf powder.
What are the risks and side effects?
The most common side effects are mild: stomach upset, headache, dizziness, and skin reactions. The most serious risk is bleeding, because ginkgo thins the blood — this matters especially if combined with blood thinners or before surgery. Some trials reported minor liver-enzyme elevations, so long-term users should have liver function checked. Raw ginkgo seeds can cause seizures, but the standardized leaf extract does not.
Who should avoid it?
Anyone on blood thinners (warfarin, aspirin, clopidogrel) or NSAIDs, anyone with a bleeding disorder, and anyone scheduled for surgery within two weeks should avoid ginkgo. People with epilepsy should use caution, and pregnant or breastfeeding women should avoid it because there is not enough safety data. As always, talk to your doctor before starting.
The Bottom Line
Ginkgo biloba is the classic “hype versus reality” case study — and the reality is more interesting than either side admits. The single most important fact is this: the two largest prevention trials ever run on any supplement, following thousands of older adults for five to six years, found that ginkgo does not prevent dementia or slow normal cognitive decline. If you are a healthy adult taking ginkgo to “protect your memory,” the best available evidence says you are probably spending money on a null result.
But that is not the whole story. The same body of research found ginkgo may offer a genuine, if modest, benefit for people who already have dementia — small-to-moderate improvements in cognition and daily function — plus solid support for vertigo and dizziness, and an excellent long-term safety record across some of the largest supplement trials ever conducted. This is a supplement whose reputation overshot, but whose remaining, narrower uses are backed by real data.
Our verdict: 🥈 Silver for specific, evidence-backed uses (symptom support in existing dementia, vertigo/dizziness), and ⚠️ for the popular “prevents memory loss” claim, which the best evidence has refuted. Who it’s for: people with early dementia symptoms seeking a modest adjunctive option (with a doctor’s sign-off), and people with vertigo or dizziness — not healthy people hoping to prevent cognitive decline. If you take it, use a standardized extract at 120–240 mg/day, mind the bleeding risk, and keep your expectations honest: ginkgo is a genuine botanical medicine with a narrow range of real uses — not a fountain of youth for the brain.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ginkgo biloba supplements are not approved to treat, cure, or prevent any disease. Always consult a qualified healthcare provider before starting any supplement, especially if you take blood thinners, have a bleeding disorder, have epilepsy, are scheduled for surgery, or are pregnant or breastfeeding. Read our full disclaimer →
Sources
- DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008. PMID 19017911
- Snitz BE, O’Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. 2009. PMID 20040554
- Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012. PMID 22959217
- Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009. PMID 19160216
- Ginkgo biloba for cognitive impairment and dementia (updated Cochrane review). Cochrane Database Syst Rev. 2026. PMID 41641880
- Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: a systematic review and network meta-analysis. Phytomedicine. 2026. PMID 41678913
- Meta-analysis of EGb 761 in mild to moderate dementia in patients with prior cerebral infarction. Front Neurol. 2025. PMID 41908799
- Effects of Ginkgo biloba extract on glycemic control, inflammatory markers, and safety in metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetol Metab Syndr. 2026. PMID 42157337
- Effects and safety of Ginkgo biloba extract on hyperlipidemia: a meta-analysis of randomized controlled trials. Pharmacology. 2026. PMID 42102021
- Ginkgo Biloba Extract Ameliorates Age-Related Mitochondrial Deficits in Human iPSCs and Their Derived Neurons and Astrocytes. Antioxidants (Basel). 2026. PMID 42351995
- Pragmatic open-label clinical trial of EGb 761 in patients with vertigo and dizziness of various aetiologies. Front Pharmacol. 2026. PMID 42568872
- Ginkgo biloba extract GBE50 alleviates vascular calcification through inhibiting the NF-κB pathway and the NLRP3 inflammasome. J Ethnopharmacol. 2026. PMID 42155821
- Evaluating dosing guidelines for Ginkgo biloba: an evidence-based approach to standardisation. Regul Toxicol Pharmacol. 2026. PMID 42269907
- Ginkgo biloba Leaf Extracts in Global Dementia and Mild Cognitive Impairment Guidelines: A Review. Planta Med. 2026. PMID 42532103
- Standardized Extract of Ginkgo biloba L. Reverses Memory Impairment in Older Female Mice with Basal Forebrain Cholinergic Dysfunction. Neurochem Res. 2026. PMID 42443567
- Age-dependent epigenetic control of flavonoid metabolism underlies chemical defenses in ancient Ginkgo biloba. Plant Cell. 2026. PMID 42363742
- Neuroprotective Effects of Ginkgo biloba Extract in Neurological Disorders: Integrating Anti-Inflammatory and Antioxidant Mechanisms. Complement Med Res. 2026. PMID 42207745